Table 5.
Nanoparticles-conjugated Cur formulae, characteristics and their biological effects [11].
| Nanoparticles | Schematic Diagram | Shape | Size (nm) | Methods | Outcome |
|---|---|---|---|---|---|
| Liposome |  |
Globular | 25–205 | In vitro, in vivo (dogs & mice) | Increased solubility, tissue distribution, and stability |
| Micelles |  |
Spherical | 10–100 | In vitro, In vivo (mice) | Increased solubility and bioavailability; Improved anti-oxidative properties |
| Noisome |  |
Lamellar | 190–1140 | In vitro, In vivo (snake and mice) | Increased skin penetration; Prolonged delivery system |
| Nanogel network |  |
Cross-linked polymer | 10–200 | In vitro | Increased stability, fluorescence effects, developed bioavailability, get better control release; Prolonged half-life |
| Chitosan |  |
Linear polysaccharide composed | 100–250 | In vitro, In vivo (rats and mice) | Improved chemical stability, improved antioxidant effects; Prolonged blood circulation |
| Gold |  |
Globular | 200–250 | In vitro | Improved solubility; Enhanced antioxidant |
| Silver |  |
Film layer | ~15 | In vitro | Improved wound healing; Increased antiviral and anticancer effects |
| Cyclodextrin |  |
cyclic oligomers of glucose oligosaccharide | In vitro | Improve stability and bioavailability of Cur | |
| Dendrimer |  |
Globular polymer | 15–150 | In vitro, In vivo (mice) | Improved stability; Increased antitumor and anti-proliferative effects |
| Solid lipid |  |
Spherical | 50–1000 | In vitro, In vivo (rat and mice) | Prolonged circulation of blood; Increased anti-inflammatory effects; Improved brain delivery |